Different induction therapies for kidney transplantation with living donor

Nga, Hong Si; Garcia, Patrícia Carvalho; Contti, Mariana Moraes; Takase, Henrique Mochida; Carvalho, Maria Fernanda; Andrade, Luís Gustavo Modelli de

doi:10.5935/0101-2800.20150033

Cited by 8 publications

(8 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the multivariate analysis, the variable associated with a better renal outcome was induction therapy (basiliximab or thymoglobulin use), as previously demonstrated in this study, 20 and similar results were found by de Castro et al 21 …”

Section: Discussionsupporting

confidence: 88%

Evaluation of the 1000 renal transplants carried out at the University Hospital of the Botucatu Medical School (HCFMB) - UNESP and their evolution over the years

et al. 2018

Self Cite

View full text Add to dashboard Cite

Introduction: The progress in kidney transplantation has been evident over the years, as well as its benefits for patients. Objectives: To evaluate the 1.000 kidney transplants performed at the Botucatu Medical School University Hospital, subdividing the patients in different periods, according to the current immunosuppression, and evaluating the differences in graft and patient survival. Methods: Retrospective cohort analysis of the transplants performed between 06/17/87 to 07/31/16, totaling 1,046 transplants, subdivided into four different periods: 1) 1987 to 2000: cyclosporine with azathioprine; 2) 2001 to 2006: cyclosporine with mycophenolate; 3) 2007 to 2014: tacrolimus with antimetabolic; and 4) 2015 to 2016: tacrolimus with antimetabolic, with increased use of the combination of tacrolimus and mTOR inhibitors. Results: There was an increase in the mean age of recipients and increase in deceased donors and their age in the last two periods. There was a reduction in graft function delay, being 54.3% in the fourth period, compared to 78.8% in the first, p = 0.002. We found a reduction in acute rejection, being 6.1% in the last period compared to 36.3% in the first, p = 0.001. Urological complications and diabetes after transplantation were more frequent in the first two periods. The rates of cytomegalovirus infection were higher in the last two periods. There was an improvement in graft survival, p = 0.003. There was no difference in patient survival, p = 0.77 (Figure 2). Conclusion: There was a significant increase in the number of transplants, with evolution in graft survival, despite the worsening in the profiles of recipients and donors.

show abstract

Section: Discussionsupporting

confidence: 88%

Evaluation of the 1000 renal transplants carried out at the University Hospital of the Botucatu Medical School (HCFMB) - UNESP and their evolution over the years

et al. 2018

Self Cite

View full text Add to dashboard Cite

show abstract

“…A similar finding was reported by Nga et al in a retrospective cohort study on 90 LDKTR. Based on that study, creatinine levels at discharge and 6 months after discharge were 1.22±0.4 and 1.33±0.5 mg/dL in the thy-moglobulin group, 1.28±0.5 and 1.34±0.7 mg/dL in patients who were prescribed basiliximab, and 1.59±0.7 and 1.36±0.5 mg/dL in patients not receiving induction therapy, with no significant difference between the study groups (12).…”

Section: Discussionmentioning

confidence: 90%

Comparing the effect of induction therapy with or without antithymocyte globulin on renal allograft outcomes in live-donor kidney transplant recipients

Marghoob

Rahimian

Ataiepour

et al. 2019

Med. J. Islam. Republ. Iran

View full text Add to dashboard Cite

show abstract

“…Recent studies showed that Antithymocyte globulin was more effective in the prevention of acute rejection when compared to basiliximab. 13,15 Except the Mexican study in deceased donors. 17 In our study acute rejections between the two arms were comparable (ATG 15.2% Vs. Basiliximab 16.9%, P=0.867).…”

Section: Image 1 Discussionmentioning

confidence: 99%

Induction Therapy in Renal Transplantation With Antithymocyte Globulin and Basiliximab- A Single Centre Retrospective Study

Hareesh¹,

Sharma²

2018

jebmh

View full text Add to dashboard Cite

BACKGROUND Renal transplantation is the best available form of renal replacement therapy. Induction therapy pre-transplant reduces the incidence of graft rejections. We present a retrospective study comparing different induction methods in living donor kidney transplantation in our institute. MATERIALS AND METHODS We analysed 423 live kidney transplant recipients of our center from Dec 2010 to Nov 2015, 344 of whom received basiliximab as induction and 79 r-ATG as induction. Primary outcomes like patient survival and graft survival, secondary outcomes like graft rejections, infections, PTDM, recurrence of disease were compared. RESULTS 5yr patient survival rates were observed to be 91% and 88% respectively whereas graft survival rates were 93% and 86% respectively for ATG and basiliximab. Incidence of rejections was similar (p=0.867). Cellular rejections were more common with basiliximab (7.9% vs. 3.8%) but statistically not significant (P=0.498). Infections in the post-operative period were more common in r-ATG arm especially LRTI (P=0.011) and diarrhoeal episodes (P=0.005). Incidence of cytopenias was more in r-ATG arm during hospital stay (10.1 vs. 2.6% P=0.002) and also the later followup period (25 vs. 12.4% P<0.001). Incidence of PTDM was more in basiliximab (33.8% vs. 22.8%) arm but not significant (P=0.061). CONCLUSION ATG and basiliximab are non-inferior to one another as induction therapy. ATG is effective in high immunological risk groups with equivalent graft and patient survival with increased risk of Lower respiratory tract infections and diarrhoea in immediate post-transplant periods and increased risk for cytopenias compared to basiliximab. Basiliximab has slightly increased risk of post-transplant diabetes mellitus. Careful selection of the agent in an individual based on risk rather than a question of efficacy of agents is the key to successful transplantation.

show abstract

Different induction therapies for kidney transplantation with living donor

Abstract: The use of induction therapy resulted in lower rates of rejection in transplantation with living donor.

Cited by 8 publications

References 10 publications

Evaluation of the 1000 renal transplants carried out at the University Hospital of the Botucatu Medical School (HCFMB) - UNESP and their evolution over the years

Evaluation of the 1000 renal transplants carried out at the University Hospital of the Botucatu Medical School (HCFMB) - UNESP and their evolution over the years

Comparing the effect of induction therapy with or without antithymocyte globulin on renal allograft outcomes in live-donor kidney transplant recipients

Induction Therapy in Renal Transplantation With Antithymocyte Globulin and Basiliximab- A Single Centre Retrospective Study

Contact Info

Product

Resources

About